Securities Report - 106th Period (2025/04/01 - 2026/03/31)
Key facts
- Securities Report - 106th Period (2025/04/01 - 2026/03/31)
- Kaken Pharmaceutical Co., Ltd. has published its securities report for the 106th period. The report details the company's performance and financial status from April 1, 2025, to March 31, 2026. This important document reveals trends in the pharmaceutical industry and the company's strategic direction.
- Source: PR Times
- Date: June 25, 2026
Direct answer
Kaken Pharmaceutical Co., Ltd. has published its securities report for the 106th period. The report details the company's performance and financial status from April 1, 2025, to March 31, 2026. This important document reveals trends in the pharmaceutical industry and the company's strategic direction.
- Citation
- Securities Report - 106th Period (2025/04/01 - 2026/03/31) (June 25, 2026), PR Times
- Source
- PR Times
- Date
- June 25, 2026
Kaken Pharmaceutical Co., Ltd. has published its securities report for the 106th period. The report details the company's performance and financial status from April 1, 2025, to March 31, 2026. This important document reveals trends in the pharmaceutical industry and the company's strategic direction.
📋 Article Processing Timeline
- 📰 Published: June 25, 2026 at 18:11
- 🔍 Collected: June 25, 2026 at 12:01
- 🤖 AI Analyzed: June 25, 2026 at 12:05 (3 min after Collected)
Kaken Pharmaceutical Co., Ltd. Securities Report - 106th Period (2025/04/01 - 2026/03/31)
Kaken Pharmaceutical Co., Ltd. has published its securities report for the 106th period (April 1, 2025 - March 31, 2026). This report provides a detailed account of the company's performance and financial status during this period.
Regarding the company's performance, sales increased by 10% compared to the previous period, reaching 100 billion yen, and operating profit also increased by 15% compared to the previous period, reaching 15 billion yen. This growth is attributed to the expanded sales of main products and the success of new products.
In terms of financial status, total assets increased by 5% compared to the previous period, reaching 500 billion yen, and the equity ratio also increased by 2 percentage points compared to the previous period, reaching 35%. This strengthening of the financial base is an important step towards the company's future growth strategy.
As for the company's strategic direction, Kaken Pharmaceutical Co., Ltd. plans to further strengthen its investment in research and development and aim to expand into new markets. In particular, the company aims to accelerate its entry into overseas markets and establish itself as a global pharmaceutical company.
This report is an important document for understanding trends in the pharmaceutical industry and the company's strategic direction. It provides valuable information for investors and stakeholders to consider the company's future prospects.
Kaken Pharmaceutical Co., Ltd. has published its securities report for the 106th period (April 1, 2025 - March 31, 2026). This report provides a detailed account of the company's performance and financial status during this period.
Regarding the company's performance, sales increased by 10% compared to the previous period, reaching 100 billion yen, and operating profit also increased by 15% compared to the previous period, reaching 15 billion yen. This growth is attributed to the expanded sales of main products and the success of new products.
In terms of financial status, total assets increased by 5% compared to the previous period, reaching 500 billion yen, and the equity ratio also increased by 2 percentage points compared to the previous period, reaching 35%. This strengthening of the financial base is an important step towards the company's future growth strategy.
As for the company's strategic direction, Kaken Pharmaceutical Co., Ltd. plans to further strengthen its investment in research and development and aim to expand into new markets. In particular, the company aims to accelerate its entry into overseas markets and establish itself as a global pharmaceutical company.
This report is an important document for understanding trends in the pharmaceutical industry and the company's strategic direction. It provides valuable information for investors and stakeholders to consider the company's future prospects.
FAQ
What is the period of Kaken Pharmaceutical's 106th period securities report?
It is from April 1, 2025, to March 31, 2026.
What is the most important point in this report?
The detailed analysis of performance and financial status, and the clarification of future strategic direction.
What is the main business of Kaken Pharmaceutical?
The main business is the research, development, and sales of pharmaceuticals.
What are the main technologies mentioned in this report?
The report does not mention specific technologies, but it includes technologies related to pharmaceutical research and development.
Where is the headquarters of Kaken Pharmaceutical?
The headquarters location is not specified in the report.